

L10 ANSWER 84 OF 88 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:762798 CAPLUS <<LOGINID::20080410>>  
 DOCUMENT NUMBER: 135:308910  
 TITLE: Pharmaceutical compositions containing an aldosterone  
 synthase inhibitor and an AT1-receptor antagonist  
 INVENTOR(S): Steele, Ronald Edward  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen  
 Verwaltungsgesellschaft m.b.H.  
 SOURCE: PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001076574	A2	20011018	WO 2001-EP4116	20010410
WO 2001076574	A3	20020425		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2405895	A1	20011018	CA 2001-2405895	20010410
BR 2001010079	A	20021231	BR 2001-10079	20010410
EP 1282410	A2	20030212	EP 2001-940317	20010410
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003530343	T	20031014	JP 2001-574092	20010410
NZ 521855	A	20041029	NZ 2001-521855	20010410
HU 2003001335	A3	20060228	HU 2003-1335	20010410
NZ 534086	A	20060831	NZ 2001-534086	20010410
US 20030083342	A1	20030501	US 2002-149107	20020827
IN 2002CN01650	A	20050128	IN 2002-CN1650	20021008
NO 2002004920	A	20021127	NO 2002-4920	20021011
MX 2002PA10091	A	20030212	MX 2002-PA10091	20021011
ZA 2002008204	A	20031014	ZA 2002-8204	20021011
US 20040204444	A1	20041014	US 2004-826106	20040415
US 20050059697	A1	20050317	US 2004-940544	20040914
US 20060122217	A1	20060608	US 2005-291008	20051130
PRIORITY APPLN. INFO.:			US 2000-196742P	P 20000412
			NZ 2001-521855	A1 20010410
			WO 2001-EP4116	W 20010410
			US 2002-149107	A3 20020827
			US 2004-940544	B1 20040914
AB	The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with			

a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. A pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof is used for the prevention of, delay of progression of, and treatment of a disease or condition selected from the group consisting of hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, hypothyroidism, myocardial infarction, etc. For example, a hard gelatin capsules were prepared containing valsartan 80.0 mg, microcryst. cellulose 110.0 mg, Polyvidone K30 45.2 mg, sodium lauryl sulfate 1.2 mg, crospovidone 26.0 mg, and magnesium stearate 2.6 mg by a granulation method.

IC ICM A61K031-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT 58-93-5, Hydrochlorothiazide 102676-47-1, Fadrozole 102676-86-8, (+)-Fadrozole 107868-30-4, Exemestane 114798-26-4, Losartan 120511-73-1, Anastrozole 131833-87-9, (+)-Fadrozole hydrochloride 133040-01-4, Eprosartan 135015-84-8, ZD-8731 135070-05-2, E 1477 137862-53-4, Valsartan 138402-11-6, Irbesartan 139481-59-7, Candesartan 144701-48-4, Telmisartan 145216-43-9, SC-52458 145733-36-4, Tasosartan 146623-69-0, Sapisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)


IT 139481-59-7, Candesartan 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 139481-59-7 CAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (CA INDEX NAME)

